Next Article in Journal
Antioxidant Properties of Buffalo-Milk Dairy Products: A β-Lg Peptide Released after Gastrointestinal Digestion of Buffalo Ricotta Cheese Reduces Oxidative Stress in Intestinal Epithelial Cells
Next Article in Special Issue
Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma
Previous Article in Journal
Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer
Previous Article in Special Issue
Metformin Induces Apoptosis and Alters Cellular Responses to Oxidative Stress in Ht29 Colon Cancer Cells: Preliminary Findings
Review

Metformin in Pregnancy: Mechanisms and Clinical Applications

1
Department of Endocrinology, Epsom and St. Helier University Hospitals NHS Trust, Wrythe Lane, Carshalton SM5 1AA, Surrey, UK
2
Department of Maternal Medicine, Epsom and St. Helier University Hospitals NHS Trust, Wrythe Lane, Carshalton SM5 1AA, Surrey, UK
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(7), 1954; https://doi.org/10.3390/ijms19071954
Received: 29 May 2018 / Revised: 12 June 2018 / Accepted: 29 June 2018 / Published: 4 July 2018
(This article belongs to the Special Issue Metformin: Mechanism and Application)
Metformin use in pregnancy is increasing worldwide as randomised controlled trial (RCT) evidence is emerging demonstrating its safety and efficacy. The Metformin in Gestational Diabetes (MiG) RCT changed practice in many countries demonstrating that metformin had similar pregnancy outcomes to insulin therapy with less maternal weight gain and a high degree of patient acceptability. A multicentre RCT is currently assessing the addition of metformin to insulin in pregnant women with type 2 diabetes. RCT evidence is also available for the use of metformin in pregnancy for women with Polycystic Ovarian Syndrome and for nondiabetic women with obesity. No evidence of an increase in congenital malformations or miscarriages has been observed even when metformin is started before pregnancy and continued to term. Body composition and metabolic outcomes at two, seven, and nine years have now been reported for the offspring of mothers treated in the MiG study. In this review, we will briefly discuss the action of metformin and then consider the evidence from the key clinical trials. View Full-Text
Keywords: metformin; pregnancy; gestational diabetes; polycystic ovarian syndrome; type 2 diabetes; obesity metformin; pregnancy; gestational diabetes; polycystic ovarian syndrome; type 2 diabetes; obesity
Show Figures

Figure 1

MDPI and ACS Style

Hyer, S.; Balani, J.; Shehata, H. Metformin in Pregnancy: Mechanisms and Clinical Applications. Int. J. Mol. Sci. 2018, 19, 1954. https://doi.org/10.3390/ijms19071954

AMA Style

Hyer S, Balani J, Shehata H. Metformin in Pregnancy: Mechanisms and Clinical Applications. International Journal of Molecular Sciences. 2018; 19(7):1954. https://doi.org/10.3390/ijms19071954

Chicago/Turabian Style

Hyer, Steve, Jyoti Balani, and Hassan Shehata. 2018. "Metformin in Pregnancy: Mechanisms and Clinical Applications" International Journal of Molecular Sciences 19, no. 7: 1954. https://doi.org/10.3390/ijms19071954

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop